Gilead Rips Merck's New Bid To Restore $2.5B Patent Verdict

By Mike LaSusa (April 9, 2020, 11:32 PM EDT) -- Gilead Sciences Inc. urged the Federal Circuit on Thursday to nix a Merck & Co. subsidiary's bid for the full court to review a panel decision that wiped out a $2.5 billion verdict in a patent dispute, calling the Merck unit's "attacks" on the panel's ruling "an exercise in selective omission."

Gilead said the panel's 2-1 precedential ruling in October was "an exceedingly poor candidate for en banc review" because the majority correctly applied the law to the "largely undisputed" facts of the case. Further, Gilead said, Merck unit Idenix Pharmaceuticals LLC's bid for en banc review largely ignores most of the panel's...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!